ABPI names 5 pharmas as code-breachers; Teva wins 180-day marketing exclusivity for Evista generic;

> Lundbeck, Menarini, Bayer, HRA Pharma UK and GlaxoSmithKline ($GSK) have breached the Association of British Pharmaceutical Industries' code of practice. More

> Teva ($TEVA) has received U.S. approval for a generic of Eli Lilly's ($LLY) Evista tablets, winning the first-to-file 180 day market exclusivity. Release

> Physicians Interactive and McKesson ($MCK) are teaming up to provide Coupons on Demand, which grants healthcare providers access to medication cost-savings offers through an Internet platform. Release

> Sanofi ($SNY) is suing Actavis ($ACT) over allegedly infringing patents on its heart drug Multaq. Report | Release

> AstraZeneca ($AZN) has won U.S. approval for a pen-injector version of once-weekly diabetes med Bydureon. News

> Newcastle, U.K.-based remarketing agency, has won a contract with Fertin Pharma, the world's largest medical chewing gum maker. Report

And Finally... Prospects for Gilead's ($GILD) next-generation hepatitis C drug Sovaldi have made CEO John Martin a billionaire. More

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?